Altimmune, Inc.（ALT）股票分析ALTAltimmune, Inc.

Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed Phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Altimmune Inc is not a good buy right now due to its current price of $2.12, which is significantly lower than analyst price targets of $17 and $20, indicating potential upside but also substantial risk. The RSI of 19.36 suggests the stock is oversold, but the negative sentiment and declining performance (48.79% drop over the past year) raise concerns about its recovery. The main risk is the projected EPS of -0.14 for the next earnings report, which could further impact investor confidence.

1 analysts cover ALT: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 16.00.